Necroptosis has emerged as a new form of programmed cell death implicated in a number of pathological conditions such as ischemic injury, neurodegenerative disease, and viral infection. Recent studies indicate that TGFβ-activated kinase 1 (TAK1) is nodal regulator of necroptotic cell death, although the underlying molecular regulatory mechanisms are not well defined. Here we reported that TAK1 regulates necroptotic signaling as well as caspase 8-mediated apoptotic signaling through both NFκBdependent and -independent mechanisms. Inhibition of TAK1 promoted TNFα-induced cell death through the induction of RIP1 phosphorylation/activation and necrosome formation. Further, inhibition of TAK1 triggered two caspase 8 activation pathways through the induction of RIP1-FADD-caspase 8 complex as well as FLIP cleavage/degradation. Mechanistically, our data uncovered an essential role for the adaptor protein TNF receptor-associated protein with death domain (TRADD) in caspase 8 activation and necrosome formation triggered by TAK1 inhibition. Moreover, ablation of the deubiqutinase CYLD prevented both apoptotic and necroptotic signaling induced by TAK1 inhibition. Finally, blocking the ubiquitin-proteasome pathway prevented the degradation of key pro-survival signaling proteins and necrosome formation. Thus, we identified new regulatory mechanisms underlying the critical role of TAK1 in cell survival through regulation of multiple cell death checkpoints. Targeting key components of the necroptotic pathway (e.g., TRADD and CYLD) and the ubiquitin-proteasome pathway may represent novel therapeutic strategies for pathological conditions driven by necroptosis.
Apoptosis and necrosis are two morphologically and mechanistically distinct forms of cell death. Apoptosis is induced by death receptor-or mitochondria-mediated pathways, showing distinct morphological features including membrane blebing, cell shrinkage, nuclear fragmentation, and chromatin condensation. 1 Recent studies indicate that certain forms of necrosis occur in a highly regulated, programmed fashion. The programmed necrosis, also termed necroptosis, has been described as a caspase-independent cell death that can occur in ATP-or mitochondria-depleted settings, characterized by plasma membrane disruption, organelle swelling, cell lysis, and inflammation. [2] [3] [4] [5] Apoptosis and necroptosis are induced via specific dearth receptors such as tumor necrosis factor receptor 1 (TNFR1), among other modules.
The pleiotropic nature of TNFR1 signaling results from the formation of different signaling complexes. [6] [7] [8] Under normal conditions, ligation of TNFR1 induces the assembly of a plasma membrane bound signaling complex, termed complex I, which contains TNF receptor-associated protein with death domain (TRADD), TNF receptor-associated protein 2 (TRAF2), receptor-interacting protein 1 (RIP1), and cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2). 8 The recruitment of TGFβ-activated kinase 1 (TAK1) and the IκB kinase (IKK) complex to the complex I leads to the activation of NFκB, which drives the transcription of pro-survival genes. Under certain conditions such as inhibition of NFκB signaling or protein synthesis, the TNFR1 complex then internalizes and converts to a cell death-inducing complex, termed complex II, with additional recruitment of Fas-associated protein with death domain (FADD) and caspase 8. [8] [9] [10] TNFR1 signaling can also induce the formation of another cell death-inducing complex, known as necrosome, consisting of RIP1, RIP3, and FADD. 11 The kinase activity of RIP1 is essential for RIP1-RIP3 interaction and necroptosis, [3] [4] [5] 12 but not essential for TNFR1mediated NFκB activation. 13 RIP3 depletion has been regarded as a gold standard to differentiate necroptosis from other forms of cell death, 14 but recent studies indicated it may also alter apoptotic signaling. 15, 16 In addition to phosphorylation, unbiquitination of RIP1 has been suggested to be another important regulatory mechanism in TNFR1 signaling. TRAF2 and cIAP1/2 act as ubiquitin ligases for RIP1, and lysine 63-linked ubiquitination of RIP1 on lysine 377 is believed to prevent the formation of complex II by stabilizing complex I. 17, 18 On the other hand, the deubiquitinating enzyme cylindromatosis (CYLD) promotes necroptotic signaling by augmenting RIP1-RIP3 interaction. 19 TAK1 (gene name Map3k7), a member of the mitogenactivated kinase kinase kinase (Map3k) family, 20 has recently emerged as nodal regulator of necroptotic signaling, although the underlying molecular regulatory pathways remain poorly defined. 16, [21] [22] [23] In vivo studies showed that tissue-specific ablation of TAK1 led to spontaneous cell death, inflammation, and fibrosis in various organs, and these effects were largely reversed by TNFR1 deletion, further supporting a critical role for TAK1 in regulating TNFR1-mediated cell survival/ death signaling. [24] [25] [26] [27] Here we dissect the molecular regulatory mechanism underlying the role of TAK1 in necroptotic signaling and showed that TAK1 regulates multiple cell death checkpoints through both NFκB-dependent and -independent mechanisms.
Results

TAK1 regulates necroptotic signaling through both
NFκB-dependent and -independent mechanisms. It has been controversial as to whether TAK1 regulates the cellular sensitivity to TNFα-induced apoptosis, necroptosis, or both. 16, 21, 23, 25 We observed that ablation of TAK1 in mouse embryonic fibroblasts (MEFs) promoted the cleavage of PARP, caspase 8, and caspase 3 upon TNFα stimulation ( Figure 1a ). High mobility group box 1 (HMGB1 ), a biomarker for necroptosis, 28 was also detected from the culture supernatant upon TNFα stimulation ( Figure 1a ). Intriguingly, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a cytoplasmic protein, was more readily detectable from the supernatant compared with HMGB1, indicating that the release of GAPDH may serve as a new biomarker for plasma membrane disruption/leakage ( Figure 1a ). Both caspase cleavage and HMGB1/GAPDH release were efficiently blocked by the RIP1 kinase inhibitor necrostatin-1 (Nec-1). Although the pan-caspase inhibitor zVAD-FMK (zVAD) blocked PARP and caspase 3 cleavage, it promoted HMGB1 and GAPDH release ( Figure 1a ). Similar effect was observed using a specific TAK1 inhibitor, 5z-7-oxozeanol 29 (5z-7, Figure 1b ). Of note, addition of 5z-7 did not further increase TNFα-induced cell death in TAK1 -/ -, MEFs, confirming the specificity of this TAK1 inhibitor (Supplementary Figure S1 ). Together, these data suggest that TAK1 inhibition promotes both apoptotic and necroptotic signaling.
Next, we sought to examine if forced activation of TAK1 is sufficient to inhibit necroptotic signaling. H9c2 myocytes display high transduction efficiency with adenoviral vectors and they behave similarly to wild-type MEFs in TNFα-induced cell death response. H9c2 cells were infected with an adenovirus encoding the constitutively active mutant of TAK1 (Ad-TAK1ΔN) or β-galactosidase adenovirus (Ad-βgal) as a control, followed by stimulation with TNFα in the presence or absence of zVAD. zVAD plus TNFα induced GAPDH release in Ad-βgal-infected H9c2 cells, indicating the induction of necroptosis ( Figure 1c ). This effect was largely blocked by TAK1ΔN overexpression, suggesting that TAK1 activation is sufficient to inhibit necroptotic signaling ( Figure 1c ). TAK1ΔN overexpression was associated with auto-phosphorylation on Thr187, indicating kinase activation. 30 Of note, Ad-TAK1ΔN alone had no effect on RIP1/RIP3 expression or GAPDH release ( Figure 1c ). TAK1 has been implicated as a critical regulator of TNFαinduced activation of NFκB, a transcription factor that drives the expression of pro-survival genes. Ablation of TAK1 blocked TNFα-induced transient degradation of IκBα, and inhibition of TAK1 with 5z-7 also abrogated TNFα-induced NFκB luciferase activity (Supplementary Figure S2) . To evaluate the contribution of NFκB pathway to TNFα-induced necroptosis, H9c2 myocytes were infected with an adenovirus encoding the non-degradable IκBα mutant (IκBα-S32/36A; Ad-IκBαM) that completely blocked NFκB activity (Supplementary Figure S2) , followed by stimulation with TNFα in the presence or absence of 5z-7 for 4 h. In the absence of TAK1 inhibition, abrogation of the NFκB failed to induce PARP cleavage or necroptotisis following TNFα stimulation for 4 h (Figures 1d and e ). In addition, PARP cleavage, GAPDH release, or necroptotic cell death induced by 5z-7 plus TNFα was not altered by inhibition of the NFκB pathway (Figures 1d and e ). These data suggest that NFκB does not contribute to the acute phase of necroptosis triggered by TAK1 inhibition. Prolonged stimulation of TNFα alone for 12 h induced cell death in Ad-IκBαMinfected H9c2 cells, and addition of 5z-7 further increased TNFα-induced cell death ( Figure 1f ). Moreover, prolonged TNFα stimulation promoted GAPDH release in Ad-IκBαMinfected cells, which was blocked by the RIP1 inhibitor Nec-1 ( Figure 1g ). Inhibition of NFκB further increased GAPDH release induced by zVAD plus TNFα (Figure 1g ). On the other hand, overexpression of NFκB-p65 in H9c2 cells, which induces robust NFκB activation, 31 blocked GAPDH release induced by zVAD plus TNFα (Figure 1g ). These data suggest that inhibition of NFκB may contribute to the delayed phase of necroptosis induced by prolonged TNFα stimulation.
Importantly, overexpression of NFκB-p65 largely inhibited necroptotic cell death induced by 5z-7 plus TNFα at 4 and 12 h (Supplementary Figure S3 ). GAPDH release induced by 5z-7 plus TNFα with or without zVAD was also abrogated (Supplementary Figure S3 ). Therefore, our data reveal a novel anti-necroptotic role for NFκB, in addition to its known antiapoptotic function. Taken together, these data suggest that TAK1 regulates necroptotic signaling through an early NFκBindependent and a delayed NFκB-dependent mechanism.
Inhibition of TAK1 triggers two caspase 8 activation pathways through the induction of RIP1-FADD-caspase 8 complex as well as FLIP degradation. Consisting with the caspase cleavage results (Figure 1a , b), TNFα plus 5z-7, but not TNFα alone, induced a rapid activation of caspase 8, which was blocked by co-treatment with Nec-1 or zVAD (Figure 2a ). These data indicate that TAK1 functions to inhibit caspase activation, in addition to its anti-necroptotic effect. Wang et al. 9 identified a RIP1-depedent caspase 8 activation pathway in the setting of cIAPs depletion/inhibition, by inducing the caspase 8-activating complex consisting of RIP1, FADD, and caspase 8. We hypothesize that inhibition of TAK1 may promote caspase 8 activation through a similar mechanism. Indeed, both RIP1 and caspase 8 were detected in the FADD immunoprecipitates upon simulation with TNFα plus 5z-7 ( Figure 2b ). The RIP1-FADD-caspase 8 interaction was blocked by Nec-1, but further enhanced by zVAD, TAK1 regulates caspase activation and necroptotosis X Guo et al indicating that RIP1 kinase activity is required for the complex formation ( Figure 2b ). Of note, an upshift of RIP1 was detected upon stimulation with 5z-7 plus TNFα, indicating RIP1 auto-phosphorylation and activation (also see Figure 3a below). Cleaved caspase 8 was also detected in the FADD immunoprecipitates following 5z-7 plus TNFα, suggesting the induction of an active complex II (Figure 2b ). Consistent with a previous report by Biton et al., 32 zVAD failed to block the cleavage of caspase 8 into the p43 fragment, thus cleaved caspase 8 was also detectable in the FADD immunoprecipitates upon stimulation with zVAD, 5z-7, and TNFα. As caspase 8 is tightly regulated by FLIP, we examined the effect of TAK1 inhibition on FLIP. Strikingly, 5z-7 plus TNFα, but not TNFα alone, induced a rapid cleavage/degradation of FLIP ( Figure 2c ). Addition of Nec-1 largely reversed this effect ( Figure 2c ). This result suggests that TAK1 functions to stabilize FLIP from cleavage/degradation through a RIP1dependent mechanism. We further assessed the role of FLIP in caspase activation and necroptotic signaling using FLIP+/+ and FLIP -/ -MEFs. As expected, TNFα alone greatly increased caspase 8 activity in FLIP -/ -MEFs, whereas TNFα induced caspase 8 activity in FLIP+/+ MEFs only in the presence of 5z-7 ( Figure 2d ). Addition of 5z-7 did not further increase TNFα-induced caspase 8 activity in FLIP -/ -MEFs, indicating maximal caspase 8 activation ( Figure 2d ). However, 5z-7 plus TNFα induced a greater level of cell death compared with TNFα alone in FLIP -/ -cells (Figure 2e ), suggesting that TAK1 inhibition promotes cell death through an additional, FLIP-independent mechanism. Similarly, TNFα also induced GAPDH release in FLIP -/ -, MEFs, which was further enhanced with the addition of 5z-7 ( Figure 2f ). Intriguingly, in contrast to its effect in FLIP+/+ MEFs, Nec-1 only partially blocked GAPDH release induced by TNFα alone or 5z-7 plus TNFα in FLIP -/ -, MEFs, possibly owing to the induction of a RIP1-independent cell death under these conditions ( Figure 2f ). Moreover, the pan-caspase inhibitor zVAD inhibited PARP cleavage but promoted GAPDH release in FLIP -/ -, MEFs, indicating a switch from apoptotic to necroptotic cell death (Figure 2f ). Given that TAK1 inhibition depletes endogenous FLIP, we test if restoration of FLIP could prevent Figure 2g ). Overexpression of FLIP also partially inhibited GAPDH release induced by zVAD/5z-7/TNFα or zVAD/CHX/TNFα (Figure 2g ). Together, our data suggest that inhibition of TAK1 promotes caspase 8 activation though two independent mechanisms: Inhibition of TAK1 promotes RIP1 phosphorylation/ activation and the RIP1-RIP3-FADD necroptotic complex formation. The kinase activity of RIP1 and RIP3 is essential for the necrosome formation and necroptotic cell death. [3] [4] [5] Here, we assessed whether TAK1 exerts its anti-necroptotic effect through RIP1 and/or RIP3. Importantly, 5z-7 plus TNFα, but not TNFα alone, induced an upshift of RIP1 and RIP3 on SDS-PAGE, which was blocked by Nec-1, but further enhanced by zVAD (Figure 3a ). This result suggests that TAK1 may regulate phosphorylation of RIP1/3. Using an anti-phospho-RIP1 (Ser166) and an anti-phospho-MLKL (Ser358) antibody, we were able to detect both RIP1 and MLKL phosphorylation in HT-29 cells following stimulation with 5z-7 plus TNFα, especially in the presence of zVAD (Figure 3a) , confirming the induction of necroptotic signaling. Next, we examined if TAK1 inhibition could induce the formation of the RIP1-RIP3-FADD necroptotic complex. Indeed, both RIP1 and FADD were detected in the RIP3 immunoprecipitates from cells treated with 5z-7 plus TNFα, and the RIP1-RIP3-FADD interaction was inhibited by Nec-1, but not by zVAD ( Figure 3b ). Thus, TAK1 exerts its anti-necroptotic effect by preventing RIP1 phosphorylation/activation and the RIP1-RIP3-FADD complex formation.
Consistent with an essential role for RIP1 in death signaling, deletion of RIP1 completely blocked GAPDH release as well as RIP3 cleavage induced by 5z-7 plus TNFα (Figure 3c ). To directly test if the kinase activity of RIP1 is required in this process and to exclude possible off-target effect of the RIP1 inhibitor Nec-1, MEFs stably expressing wild-type (Wt) or the kinase-dead mutant (K45A) of RIP1 were generated by re-expressing these proteins in RIP1 -/ -cells. 5z-7 plus TNFα induced GAPDH release and RIP3 cleavage in RIP1-Wt, but not RIP1-K45A MEFs (Figure 3d ). Similarly, GAPDH release induced by 5z-7 plus TNFα was blocked in RIP3 -/ -MEFs as well as in cells expressing the kinase inactive mutant of RIP3 (D160N) (Figures 3e and f) . However, RIP1 cleavage induced by 5z-7 plus TNFα was not affected in RIP3-deficient cells, suggesting that RIP3 acts downstream of RIP1 in necroptotic signaling (Figures 3e and f) .
Consistent with the data above, necroptosis induced by 5z-7 plus TNFα was largely blocked by ablation of RIP1 or RIP3 (Figures 3g and h) . Interestingly, ablation of RIP1 or RIP3 induced a moderate increase in apoptosis following stimulation with 5z-7 plus TNFα, which was blocked by zVAD (Figures 3g and h) . Ablation of RIP3 also slightly enhanced 5z-7 plus TNFα-induced caspase 8 activity (Supplementary Figure S4 ). On the other hand, inhibition of caspases with zVAD further enhanced necroptosis in wild-type MEFs (Figures 3g and h) . These data also support a cross-talk between necroptosis and apoptosis that is delicately regulated by RIP1/RIP3 and caspases.
The adaptor protein TRADD is essential for caspase 8 activation and necrosome formation in the setting of TAK1 inhibition. To gain further mechanistic insights, we carefully examined the role of several key components of TNFR1 signaling pathway in necroptotic cell death triggered by TAK1 inhibition. Both TNFR1 and TNRF2 have been shown to mediate necroptotic cell death. 33 Here we determined that ablation of TNFR1, but not TNFR2, blocked GAPDH release and caspase 8 activation induced by 5z-7 plus TNFα (Figures 4a and b) . These data indicate that TAK1 regulates cellular sensitivity to TNFα-induced necroptotic signaling and caspase activation mainly through TNFR1. Following TNFR1 ligation, the adapter protein TRADD is rapidly recruited to the death domain of TNFR1, which is critical for the formation of downstream signaling complexes. 34 However, the role of TRADD in necroptotic signaling has not been investigated. Here we showed that deletion TRADD largely blocked PARP cleavage, caspase 8 activation, GAPDH release, and cell death induced by 5z-7 plus TNFα, indicating a critical role for TRADD in regulating both apoptotic and necroptotic signaling (Figures 4c-f ). Importantly, deletion of TRADD also prevented the RIP1/RIP3 necrosome formation induced by 5z-7 plus TNFα (Figure 4d ). Therefore, these data revealed an essential role for the adaptor protein TRADD in regulating caspase 8 activation and necrosome formation in the setting of TAK1 inhibition.
Ablation of the RIP1 deubiquitinase CYLD prevents necroptotic signaling triggered by TAK1 inhibition. Next, we tested whether the RIP1 deubiquitinase CYLD is required the TNFα-induced necroptosis in the setting of TAK1 inhibition. Remarkably, silencing of CYLD with a shRNA lentiviral vector largely blocked PARP cleavage and GAPDH release induced by 5z-7 plus TNFα (Figure 5a ). Of note, GAPDH release induced by zVAD/5z-7/TNFα or zVAD/CHX/ TNFα was also largely inhibited in CYLD-deficient cells (Figure 5a ). In addition, 5z-7 plus TNFα also induced CYLD cleavage, which was reversed by zVAD, although it is unclear how CLYD cleavage affects necroptotic signaling. Further, silencing CYLD blocked the RIP1/RIP3 necrosome formation induced by zVAD/5z-7/TNFα or zVAD/CHX/TNFα. RIP1 phosphorylation, as indicated by the mobility shift, was also attenuated (Figure 5b ). Consistent with the data above, silencing CYLD largely abolished caspase 8 activation and necroptotic cell death induced by 5z-7 plus TNFα (Figures 5c  and d) . These data suggest CYLD is critically involved in TAK1-mediated regulation of apoptotic and necroptotic signaling.
Blockade of the ubiquitin-proteasome pathway attenuates protein degradation and necroptotic signaling triggered by TAK1 inhibition. Importantly, TAK1 inhibition triggered the degradation of several signaling molecules that regulate apoptosis and necroptosis, including cIAP2, FLIP, and NFκB-p65 (Figure 6a ). This prompted us to assess the potential role of ubiquitin-proteasome pathway in regulating necroptosis. In addition to clearing damaged and misfolded proteins, the ubiquitin-proteasome pathway also regulates the availability of key signaling proteins in various cellular processes such as cell growth and proliferation, cell cycle regulation, and gene expression. Using specific proteasome inhibitors MG-132, lactacystin, or the ubiquitin-activating enzyme E1 inhibitor PYR-41, we showed that blocking the ubiquitin-proteasome pathway effectively inhibited PARP cleavage and GAPDH release induced by 5z-7 plus TNFα, an effect comparable to Nec-1 (Figure 6a ). More importantly, the degradation of cIAP2, FLIP, and NFκB-p65 was also largely abolished (Figure 6a ). We further examined whether inhibition of proteasome pathway affects the necrosome formation. Indeed, similar to Nec-1, pretreatment with MG-132, lactacystin, or PYR-41 also blocked the RIP1-RIP3-FADD necroptotic complex formation induced by 5z-7 plus TNFα (Figure 6b ). Pretreatment with MG-132, lactacystin, or PYR-41 also attenuated caspase 8 activity and necroptotic cell death induced by 5z-7 plus TNFα (Figures 6c and d) . Taken together, these data suggest that the ubiquitin-proteasome pathway regulates death signaling by controlling the availability of key pro-survival signaling proteins FLIP, cIAP2, and NFκB-p65.
Discussion
Our results demonstrated that TAK1 functions as a nodal regulator of the TNFR1-mediated cell survival/death signaling through regulation of multiple cell death checkpoints. Here we showed that inhibition of TAK1 inactivates NFκB, a cell death checkpoint for apoptosis and necroptosis (Figure 6e ). TAK also regulates cell death through an acute NFκB-independent (Figure 6e ). Inhibition of TAK1 promoted phosphorylation and activation of RIP1, which is essential for the formation of both cell death complexes. Ablation of the RIP1 deubiquitinase CYLD largely blocked apoptotic and necroptotic cell death induced by TAK1 inhibition. We also identified an indispensable role for the adaptor protein TRADD in TNFα-induced necroptotic signaling. Finally, we identified the ubiquitin-proteasome pathway as a novel necroptotic regulatory mechanism by controlling the availability of key pro-survival signaling proteins, including FLIP, cIAPs, and NFκB (Figure 6e ).
Although the anti-apoptotic role of the NFκB has been well established, its role in regulating necroptosis remains elusive. 25 Here we provide evidence that the acute phase of TNFα-induced necroptosis triggered by TAK1 inhibition is NFκB-independent but the late-onset necroptosis is NFκBdependent. Moreover, activation of NFκB by overexpressing p65 blocked both apoptotic and necroptotic signaling induced by 5z-7 plus TNFα. Similarly, overexpression of IKK2-EE, an NFκB activator, was shown to inhibit TRAIL-induced cell death in TAK1 -/ -, MEFs. 35 The anti-necroptotic effect of NFκB was likely due to the upregulation of pro-survival genes such as FLIP and cIAPs. Indeed, overexpression of FLIP partially abrogated necroptotic cell death induced by 5z-7 plus TNFα. Therefore, our data support a model that TAK1 prevents apoptotic and necroptotic cell death through both NFκBindependent and NFκB-dependent checkpoints.
We showed that RIP1 kinase activity is essential for the induction of cell death complexes and apoptotic/necroptotic cell death in TAK1-deficient cells. We speculate that TAK1 inhibition may promote RIP1 phosphorylation/ activation through degradation of cIAPs. Indeed, depletion of cIAPs has been shown to induce RIP1 phosphorylation/activation in L929 cells. 22 Moreover, our recent studies showed that TAK1 prevents cell death complex formation by interacting and stabilizing RIP1 in the complex I. 24 When TAK1 is inhibited or depleted, RIP1 switches its binding partner by dissociating from TAK1 and associating with FADD/caspase 8 or RIP3 to form the caspase 8-activating complex or the RIP1-RIP3 necrosome. In line with these results, forced activation of TAK1 blocked cell death complex formation and necroptotic cell death, further suggesting that TAK1 exerts its anti-necroptotic effect by preventing RIP1 activation.
Although TRADD has been shown to be indispensable for TNFα-induced apoptosis, 34, 36 its role in necroptotic signaling remains unclear. 37, 38 Our data uncovered an essential role of TRADD in necroptotic signaling in the setting of TAK1 inhibition and established TRADD as an upstream regulator of both apoptotic and necroptotic signaling. Whether CYLD is required for TNFα-induced necroptosis has been controversial. 8, 15, 22 Here we showed that ablation of CYLD largely blocked caspase activation as well as the RIP1-RIP3 necrosome formation induced by TAK1 inhibition. We speculate that the deubiquinating activity of CYLD is required for RIP1 kinase activation and subsequent necrosome formation in the setting of TAK1 inhibition. In addition, CYLD has also been shown to function as a deubiquitinating enzyme for TAK1 and negatively regulates its activity. 39 Thus, repression of CYLD may prevent cell death at the level of both TAK1 and RIP1. Finally, we identified the ubiquitin-proteasome pathway as a previously unidentified regulatory mechanism of necroptosis. Inhibition of TAK1 promoted destabilization and degradation of key proteins of the necroptotic signaling pathway, including FLIP, cIAPs, NFκB-p65, and possibly other signaling proteins.
Importantly, inhibition of the ubiquitin-proteasome pathway attenuated protein degradation, caspase activation, necrosome formation, as well as necroptotic cell death, thus revealing a critical role for the ubiquitin-proteasome pathway in regulating necroptosis. Further study is needed to determine how the ubiquitin-proteasome pathway is regulated in necroptosis and how this pathway can be specifically targeted in pathological conditions. In summary, we identified new Targeting key components of the necroptotic pathway (e.g., TRADD and CYLD) and the ubiquitinproteasome pathway may represent a valid therapeutic strategy for pathological conditions driven by necroptosis.
